Literature DB >> 19789697

Acute chest pain in a patient treated with capecitabine.

C Camaro1, P W Danse, H A Bosker.   

Abstract

A 61-year-old male with a history of metastatic colorectal cancer was referred to our hospital for primary coronary intervention because of acute ST-elevation myocardial infarction. Coronary angiography, however, revealed no significant stenoses. When asked, the patient revealed that capecitabine (Xeloda(R)) was started by his oncologist one day before admission. It is known that this oral 5-FU analogue drug, used in metastatic colorectal cancer, can cause coronary artery spasms. The main treatment of capecitabine-induced vasospasm is discontinuation of the drug. Indeed, after cessation of the drug the patient remained free of symptoms and the ECG abnormalities normalised. (Neth Heart J 2009;17:288-91.).

Entities:  

Year:  2009        PMID： 19789697      PMCID： PMC2743818          DOI： 10.1007/BF03086268

Source DB:  PubMed          Journal:  Neth Heart J        ISSN： 1568-5888            Impact factor:   2.380


  16 in total

1.  Coronary spasm induced by capecitabine.

Authors:  B Schnetzler; N Popova; C Collao Lamb; A P Sappino
Journal:  Ann Oncol       Date:  2001-05       Impact factor: 32.976

2.  Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis.

Authors:  J J Boyle; B Wilson; R Bicknell; S Harrower; P L Weissberg; T P Fan
Journal:  J Pathol       Date:  2000-10       Impact factor: 7.996

3.  Capecitabine-induced coronary vasospasm.

Authors:  Yuliya B Goldsmith; Nancy Roistacher; Michael S Baum
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

4.  Coronary artery spasm induced by capecitabine.

Authors:  Alfonso Sestito; Gregory Angelo Sgueglia; Carmelo Pozzo; Alessandra Cassano; Carlo Barone; Filippo Crea; Gaetano Antonio Lanza
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2006-02       Impact factor: 2.160

5.  Acute coronary syndrome induced by capecitabine therapy.

Authors:  Namal Wijesinghe; Paul I Thompson; Hugh McAlister
Journal:  Heart Lung Circ       Date:  2006-05-12       Impact factor: 2.975

6.  Acute chest pain in a patient treated with capecitabine.

Authors:  C Camaro; P W Danse; H A Bosker
Journal:  Neth Heart J       Date:  2009-08       Impact factor: 2.380

7.  Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.

Authors:  N Frickhofen; F J Beck; B Jung; H G Fuhr; H Andrasch; M Sigmund
Journal:  Ann Oncol       Date:  2002-05       Impact factor: 32.976

8.  Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Authors:  W Scheithauer; J McKendrick; S Begbie; M Borner; W I Burns; H A Burris; J Cassidy; D Jodrell; P Koralewski; E L Levine; N Marschner; J Maroun; P Garcia-Alfonso; J Tujakowski; G Van Hazel; A Wong; J Zaluski; C Twelves
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

9.  Capecitabine-induced coronary vasospasm--a case report.

Authors:  Asad A Rizvi; Peter Schauer; Dariush Owlia; James E Kallal
Journal:  Angiology       Date:  2004 Jan-Feb       Impact factor: 3.619

10.  [Myocardial ischaemia as a result of treatment with capecitabine].

Authors:  H K van Halteren; A H Liem; A S T Planting
Journal:  Ned Tijdschr Geneeskd       Date:  2007-06-30
View more
  12 in total

1.  Epicardial coronary artery spasm as cause of capecitabine-induced tako tsubo cardiomyopathy.

Authors:  Thomas Klag; Giulio Cantara; Peter Ong; Martin Kaufmann; Udo Sechtem; Anastasios Athanasiadis
Journal:  Clin Res Cardiol       Date:  2013-11-26       Impact factor: 5.460

2.  Case histories: increasing role for major journals.

Authors:  E E van der Wall; A A M Wilde
Journal:  Neth Heart J       Date:  2009-08       Impact factor: 2.380

3.  Acute chest pain in a patient treated with capecitabine.

Authors:  C Camaro; P W Danse; H A Bosker
Journal:  Neth Heart J       Date:  2009-08       Impact factor: 2.380

4.  Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer.

Authors:  Omar Dzaye; Suzy Cleator; Petros Nihoyannopoulos
Journal:  BMJ Case Rep       Date:  2014-09-22

Review 5.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

6.  Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?

Authors:  Jun Chong; Andrew Fw Ho; Jonathan Yap; Heerajnarain Bulluck; Derek J Hausenloy
Journal:  Cond Med       Date:  2019-10

Review 7.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.

Authors:  Anne Polk; Kirsten Vistisen; Merete Vaage-Nilsen; Dorte L Nielsen
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-04       Impact factor: 2.483

8.  What the Cardiologist Needs to Consider in the Management of Oncologic Patients with STEMI-Like Syndrome: A Case Report and Literature Review.

Authors:  Aneta Aleksova; Giulia Gagno; Alessandro Pierri; Carla Todaro; Alessandra Lucia Fluca; Valentina Orlando; Alessandra Guglielmi; Antonio Paolo Beltrami; Gianfranco Sinagra
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-12

9.  Myocardial infarction caused by pharmacological substances - case description and literature review.

Authors:  Tomasz Kameczura; Leszek Bryniarski; Sławomir Surowiec; Maryla Kocowska; Kalina Kawecka-Jaszcz; Danuta Czarnecka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-09-16       Impact factor: 1.426

10.  Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?

Authors:  Caterina Fontanella; Marianna Aita; Marika Cinausero; Giuseppe Aprile; Maria Grazia Baldin; Veronica Dusi; Chiara Lestuzzi; Gianpiero Fasola; Fabio Puglisi
Journal:  Onco Targets Ther       Date:  2014-09-29       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.